Both neopterin and biopterin concentrations ill cerebrospinal fluid from patients with Parkinson's disease, in which the nigrostriatal dopamine neurons degenerate, were lower than those from agematched older control subjects. However, the decrease in biopterin was more marked than that in neopterin, resulting in the increase in the neopterin/ biopterin ratio in Parkinson's disease. These results suggests that neopterin in cerebrospinal fluid in Parkinson's disease may partiy be derived from immunoactivated glial cells, besides catecholamine or serotonin n eurons including nigrostriatal dopamine neurons . In accordance to this hypothesis, cytokines (TNF-a, IL-ll3, IL-2 , IL-6, EGF, TGF-a, TGF-131) were te.mnd to be increased in the striatum and/or in cerebrospinal fluid . The increment of cytokines in the brain in Parkinson's disease may be related to the mechanism of neurodegeneration of dopaminergic neurons in Parkinson's disease . In contrast to Parkinson's disease, in hereditary progressive dystonia/ dopa-responsive dystonia, which is a dopamine deficiency caused b y mutations in GTP cyclohydrolase I w ithout neuronal cell death (Segawa 's disease ), neopterin and biopterin in cerebrospinal fluid decreases in parallel owing to the decreased activity in GTP cyclohydrolase I .
Introduction
Parkinson's disease is caused by cell death of the nigrostriatal dopaminergic neurons. As our knowledge of parkinsonian cell death increases, it appears that there are many factors; oxidative stress and cytotoxicity of reactive oxygen species, lack of neurotrophic factors, endogenous and exogenous neurotoxins, mitochondrial abnormalities and ATP deficiency . These factors could be interactive ( 1) . We questioned whether an § Correspondence: T. Nagatsu, Division of Molecular Genetics, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi 470-1192 Japan.
immune response 111 the nigrostriatal dopaminergic neurons may occur in the process of cell death in Parkinson 's disease, influencing either cell death or compensatory maintenance of the dopam inergic neurons. For asking this question, we measured neopterin and cytokines as immune markers in cerebrospinal fluid and the brain (striatum ) from patients with Parkinson's disease . The results showed an increased neopterin/ biopterin ratio in cerebrospinal fluid and increased levels of cytokines in the striatum from patients with Parkinson's disease , and suggest that immune reaction may be involved at least in part in the pathogenesis of Parkinson's disease. In contrast to Parkinson's disease, in hereditary pro-gressive dystonia/dopa-responsive d ystonia which is caused by mutations in the GTP cyclohydrolase I gene, the first e n zyme for synthesizing tetrahydrobiopterin, the cofactor of tyrosine hydroxylase, a dopamine deficiency occurs specifically in the nigrostriatal dopamien neurons without cell death, and neopterin and biopterin decreases In parallel with a normal neopterin/biopterin ratio.
Neopterin and biopterin in cerebrospinal fluid from patients with Parkinson's disease
Parkinson's disease is pathologically characterized by selective cell lose of the nigrostriatal dopaminergic neurons in the brain. Thus, all the biochemical markers of dopamine synthesis, including the activity, protein and mRNA of tyrosine hydroxylase (the first enzyme of dopamine synthesis), biopterin (the cofactor of tyrosine hydroxylase), and GTP cyclohydrolase I activity (the first enzyme of tetrahydrobiopterin synthesis), are decreased in the nigrostriatum (2) (3) (4) (5) . The decrease in biopterin in cerebrospinal fluid in Parkinson's disease is thought to be due to degeneration of nigrostriatal dopaminergic neurons, which may be a main source of biopterin in cerebrospinal fluid .
We simultaneously measured hiopterin and neopterin In cerebrospinal fluid from normal controls and from patients w ith ParkinsonOs disease (6) .
We split the normal controls into two groups: (i) 50 years or younger and (ii ) 52 years or older.
As shown in Eg. 1, the concentration of neopterin and the neopterin/biopterin ratio in cerebrospinal fluid of the younger group (i) were significantly lower than those of the o lder group (ii ). The biopterin concentration in cerebrospinal fluid were lower in the o lder group (ii ) than in the younger group (i), but the difference was not significant. The concentrations of both biopterin and neopterin in cerebrospinal fluid from patients with Parkinson's disease were lower than those of either the younger control group (i) or the agematched, older control group (ii) (P < 0.001). The neopterin/biopterin ratio was significantly higher than that of the younger control group (i), and was slightly higher than that of the agematched, o lder control group (ii ). These results indicate that although in normal aging of the brain both neopterin and biopterin are decreased in the brain, neopterin may be decreased more slow ly than biopterin. This suggests that a part of neopterin may be produced from g lial cells besides neopterin-synthesizing neurons. These changes appear to be accerelat ed in Parkinson's disease ; a more drastic decrease in biopterin and a slower decrease in neopterin.
These changes in biopterin and neopterin in cerebrospinal fluid 111. Parkinson 's disease are shown more clearly when the patients are classified by the disease stages according to the criteria reported by Hohen and Yahr; biopterin concentrations were markedly decreased, but neopterin concentrations and the neopterin/ biopterin ratios were increased during the progress of disease from stage II to stage IV (Fig. 2 ) .
Since neopterin is thought to be produced not only from biopterin-synthesizing neurons, but also from immuno-activated glial cells, the results may suggest some implication of immune response in Parkinson's disease. (HPD) or dopa-responsive dystonia (DRD) Hereditary progressive dystonia with marked diurnal f1uctuation ( HPD) was originally described b y Segawa et al. (7) as a hereditary progressive striatal disorder. The disease is caused by dopamine deficiency in the striatum like Parkinson 's dise ase. L -Dopa to supplement dopamine in the striatum gives a marked and sustained response with relatively low doses without apparent side effects. The gene for HPD / D RD was mapped to chromosome 14q (8, 9 ) . We cloned the human GTP cyclohydrolase I gene ( 10 ) , and mapped the gene to 14q 22 .1-22.2 within the HPD/ DRD locus (11) . We confirmed that the GTP cyclohydrolase I gene is a causative gene for HPD/ DRD, based on the identification of mutations of the gene in patients with HPD / DRD and a marked decrease in the enzyme activity expressed in mononuclear blood cells ( 11 ) . The activity of GTP cyclohydrolase I in mononuclear blood cells were from 2 to 20% of the control values. We found carriers without any symptoms who had the same mutation as the patients, and the GTP cyclohydrolase I activity in mononuclear blood cells were about 40% of the normal values (11 ) .
Changes in neopterin in hereditary progressive dystonia with marked diurnal fluctuation
Neopterin content in cerebrospinal fluid, which is thought to reflect the GTP cyclohydrolase I activity in the brain, was reported to be less than a bout 20% of normal levels ill HPD/ DRD patients, while an unaffected carrier of HPD / DRD showed 35 % neopterin content compared with normals ( 12,13 ). Furukawa et al. ( 12) reported two cases (6 years and 5 years at cerebrospinal fluid analyses ) of HPD / DRD whose cerebrospinal fluid showed the biopterin level of 7 .1 and 5 .9 pmolj ml and the neopterin level of 4.4 pmoljml and 4.3 pmoljml, respectively. Thus, the neopterin/biopterin ratio of those two HPD/ DRD cases were about 0 .62 and 0 .73. These values are similar to our control values for the younger control group (0.96 ± 0 .40), and much lower than the value ( 3 .18 ± 1.11 ) in the parkinsonian patients at stage 4 (6 ), (Figs. 1 and 2 ). These results suggest that in HPD/ DRD both neopterin and biopterin may be decreased in parallel with the ratio similar to that of the normal younger group (i) in our study (6 ) . The norm a l neopterin/biopterin ratio in cerebrospinal fluid from patients with HPD/ DRD and the higher ratio in patients with Parkinson 's disease may correspond to the absence or presence of cell death of the nigrostriatal dopamine neurons.
The symptom of HPD / DRD may appear when the levels of GTP cyclohydrolase I activity and biopterin in the brain are decreased to less than 20% of their normal levels. As a result of dePteridines/Vol. 10 creases in G T P cyclohydrolase I aCtlVlty and the biopterin level, the activity of tyrosine h ydroxylase and the dopamine level In th e nigrostriatal dopam in e neurons 111 HPD jDRD may be reduced to 2-20% of the n ormal level to manifest the symptom. These resu lt s also inclicat e that the nigrostriatal dopamine neurons may be most susceptible to the decreases in GTP cyclohydrolase I activity, biopterin, tyrosine hydroxylase activity, and dopamine. After our first discovery of GTP cyclohydrolase I mutations in HPD/ DRD in 1994, about 40 families/patients of HPD /DRD were reported in all over the world; the mutations in the coding region of GTP cyclohydrolase I gene in HPD / DRD were missense mutations , nonsense mutations, and frameshift mutations ( 11, 14-34) Table 1 ) . However, about 40% of HPD/ DRD patients did not show mutations in the coding region or exon-intron junctions of the GTP L\'clohydrolase I gene .
Autosomal recessive GTP cyclohydrolase I deficiency was first reported III 1984 by ~iederwieser, Blau et al. (35) . We (10,36) found 3 different missense mutations in both alleles of GTP cyclohydrolase I gene in GTP cyclohydrolase I deficiency (11,33; Ichinose, H. et al. to be published) ( Table 1 ). In recessively inherited GTP cyclohydrolase I deficiency, the enzyme activity in the liver and neopterin and biopterin in cerebrospinal fluid were undetectable. Blau et al. (37) measured GTP cyclohydrolase I activity in mononuclear blood cells with a family of GTP cyclohydrolase r deficiency. The homozygous patient had no enzyme activity. The heterozygous parents, the father and mother \\'ithout symptoms had 30% and 46% of the control values. The results agree with our finding that the symptom of dystonia may appear when the GTP cyclohydrolase I activity is decreased to less than 20% of the normal value. It should be noted that the phenotypes of recessive GTP cyclohydrolase I deficiency are completely different from those of dominant HPD/DRD and very severe. The enzyme activity of the mutants expressed in Escherichia coli was undetectable ( 10) . Thus, decreases in all pterin -dependent enzymes, such as phenylalanine hydroxylase, tyrosine hydroxylase, tryptophan hydroxylase, and probably nitric oxide synthase, may cause decreases in dopamine, norepinephrine, epinephrine, serotonin, and possibly nitric oxide. Such decreases in various important neurotransmitters would produce complex and severe symptoms. In fact, severe neurological symptoms besides limb dystonia in HPD /DRD were observed in recessive GTP cyclohydrolase I deficiency; hyperphenylalaninemia due to deficiency of liver phenylalanine hydroxylase, truncal muscle hypotonia, mental retardation, epileptic convalsions, and fever episodes probably due to combined deficiencies of catecholamines and serotonin.
Dystonia with motor delay m compound heterozygotes for GTP cyclohydrolase I gene mutations were recently reported (33) . In the compound heterozygotes, tetrahydrobiopterin levels in cerebrospinal fluid were lower than those in HPD/DRD, and the symptoms were intermediate between mild HPD /DRD with only dystonia and GTP cyclohydrolase I deficiency with severe neurological symptoms (33) .
All these results suggest that a partial (2-20%) decrease in the nigrostriatal dopamine neurons due to partial decreases in GTP cyclohydrolase I activity, tetrahydrobiopterin level, tyrosine hydroxylase activity, and dopamine may cause the symptoms of HPD/DRD. This hypothesis is also supported by the findings of recently reported autosomal receSSive DRD, ll1 which a point mutation ll1 tyrosine hydroxylase (Gln381 Lys ) results in the symptom of DRD (38). The mutant tyrosine hydroxylase had the activity of about 15% of the corresponding wild-type tyrosine hydroxylase when expressed in Escherichia coli (39). Another recessive DRD patient with a point mutation (Leu205Pro), which caused a lower actiVIty (-1. 5% of the wild type tyrosine hydroxylase in Escherichia coli), produced severe clinical phenotype of parkinsonism (40) . These results in recessive DRD suggest that reduction of tyrosine hydroxylase activity and dopamine level to less than 2% of the normal level may affect not only nigrostriatal dopamine neurons but also other catecholamine or serotonin neurons, producing the phenotype of parkinsonism rather than DRD. The severe symptoms of compound heterozygous DRD (33) and GTP cyclohydrolase r deficiency agree with this hypothesis.
Changes in cytokines in Parkinson's disease
Parkinson's disease is also a nigrostriatal dopamine deficiency. However, it is different from HPD /DRD ill that cell death of the nigrostriatal dopamine neurons occurs in Parkinson's disease ( 1 ) , and that the dopamine deficiency in the striatum is a result of cell death . Our finding on relative increase in neopterin in cerebrospinal fluid in Parkinson's disease may suggest the possibility of production of neopterin form glial cells with the decrease in neopterin in the dopamine neurons, owing to immune activation in Parkinson's disease . We, therefore, measured various cytokines and neurotrophines Cytokines and neurotrophines except bFGF were elevated specifically in the striatum, but not in the cerebral cortex from the patients with Parkinson's disease (Table 2) . Cytokine levels in LCSF were very low compared with those in VCSF except TNF-a. The TNF-a level was significantly detected inLCSF in controls and was increased ill Parkinson's disease (Table 3 ) (41) (42) (43) (44) (45) . We found that apotosis related proteins such as bcl-2 and soluble Fas were increased in the striatum in Parkinson's disease (46, 47) . There were significantly positive correlations between the levels of sFas and those of 1L-1J3, IL-6, bcl-2, and TNF-a (47).
Our results suggest that up-regulation of cytokines, neurotrophines, and apoptosis-related proteins may be involved in the pathogenesis of neurodegeneration in Parkinson 's disease. Cytokines act as growth and/or differentiation factors of cells in the brain.
It is interesting to note that lesions in the The results suggest that immune response may occur in the nigrostriatal regions of parkinsonian brain. The expression of major histocompatibility complex-1 (MHC-1) in the glial cells may be associated with an increase in J32-microgloblin that is one component of MHC-l. We found that J32-microgloblin level was increased in the striatum in Parkinson's disease (44) . This suggests that the expression of MHC-1 antigens may also be elevated in the parkinsonian striatum. The induction of MHC-1 antigen/[32-microglobulin '\'iicroglial cells and astrocytes are thought to be the most probable candidates to produce (\"tokines in the parkinsonian brain . These glial (dis may also produce neopterin and contribute :n the relatively small decrease in neopterin level -' . . . . compared to the large decrease in the biopterin ;c\"C1 in cerebrospinal fluid in Parkinson's disase.
TNF-a/TNF-a receptor was also reported to be increased in the parkinsonian brain (49, 50) . IL-11), IL-6, TGF-I)l and TGF-1)2 in cerebrospinal fluid were also reported to be increased in Parkinson's disease (51, 52) .
The changes in cytokines and neurotrophins may also suggest that the cell death of the nigrostriatal dopamine neurons may be apoptosis (53, 54) .
Conclusion
Hereditary HPD/DRD is a striatal dopamine deficiency caused by mutations in the genes in dopamine synthesizing enzymes, GTP cyclohydrolase I or tyrosine hydroxylase, and may show normal neopterin/biopterin ratio in cerebrospinal fluid. In contrast, the changes in neopterin and cytokines in the cerebrospinal fluid and in the brain (striatum) in Parkinson's disease suggest possible implication of immune response and the resultant apoptotic cell death in the pathogenesis of Parkinson 's disease. New therapeutic and neuroprotective approach for therapies against Parkinson's disease could be developed by immunosuppresive drugs and inhibitors in the pathway of apoptotic cell death.
